2,8-Dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole;hydron;dichloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,8-Dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole;hydron;dichloride
• 英文别名: 2,8-dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole;hydron;dichloride
• 化学式: C13H20Cl2N2
• mdl: MFCD00444963
• 分子量: 275.21
• InChiKey: XWLFAMANDIWUKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.63
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  15.3
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• Methods and compositions for treating Huntington's disease
  申请人：Hung David

  公开号：US20070117834A1

  公开（公告）日：2007-05-24

  The invention provides method for treating Huntington's disease, slowing the onset and/or development and/or progression of Huntington's disease or preventing the development of Huntington's disease using hydrogenated pyrido[4,3-b]indoles, including dimebon.

  这项发明提供了一种治疗亨廷顿病的方法，通过使用氢化吡啶并呋[4,3-b]吲哚类化合物，包括二甲苯胺，来减缓亨廷顿病的发病、发展和/或进展，或预防亨廷顿病的发展。
• METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE
  申请人：Hung David T.

  公开号：US20100152108A1

  公开（公告）日：2010-06-17

  The invention provides methods and combination therapies for treating and/or preventing and/or slowing the onset and/or development of Alzheimer's disease using a hydrogenated pyrido (4,3-b) indole (e.g., dimebon) in conjunction with another compound, pharmaceutically acceptable salt thereof or therapy for Alzheimer's disease.

  该发明提供了一种治疗和/或预防和/或减缓阿尔茨海默病的发作和/或发展的方法和联合疗法，使用氢化吡啶并哌啶(例如二甲苯胺)与另一化合物、其药用盐或治疗阿尔茨海默病的疗法结合。
• Optical Isomers of (+) and (-)-Trans-2,3,4,4A,5,9B-Hexahydro-2,8-Dimethyl-1H-Pyrido[4,3-B] Indole
  申请人：Salimov Ramiz Medzhidovich

  公开号：US20080262019A1

  公开（公告）日：2008-10-23

  The present invention represents novel optical isomers produced according the invention that are optic antipodes to each other having individual biological activity which can be used as active ingredients in pharmaceutical compositions with nootropic and sedative activity for treatment of different individual conditions of patients.

  本发明代表了根据本发明制备的新型光学异构体，它们是光学对映体，具有各自的生物活性，可以用作药物组合物的活性成分，具有脑功能增强和镇静作用，用于治疗患者的不同病况。
• AGENT FOR TREATING NEURO-DEGENERATIVE DISORDERS
  申请人：Zefirov, Nikolai Serafimovich

  公开号：EP0876818A2

  公开（公告）日：1998-11-11

  Hydrogenated pyrido(4,3-b)indoles of general formula (I) in which R1, R2 and R3 have the meanings indicated in the description and have the properties of NMDA-antagonists and are suitable for use in treating neurodegenerative disorders, especially Alzheimer's disease.

  通式(I)的氢化吡啶并(4,3-b)吲哚，其中 R1、R2 和 R3 的含义如描述所示，具有 NMDA 拮抗剂的特性，适用于治疗神经退行性疾病，尤其是阿尔茨海默病。
• Agents for treating neurodegenerative disorders
  申请人：——

  公开号：US20010020028A1

  公开（公告）日：2001-09-06

  Compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease, are provided. The compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I): 1 wherein R 1 is Me, Et or PhCH 2 ; R 2 is H, PhCH 2 or 6-Me-3-Py-(CH 2 ) 2 ; and R 3 is H, Me or Br. The solid line accompanied by the dotted line, i.e. +E,uns - - - represents a single or double bond and salts thereof with pharmacologically acceptable acids and quaternary derivatives.

  本文提供了用于治疗神经退行性疾病，尤其是阿尔茨海默病的化合物和方法。所提供的用于治疗神经退行性疾病的化合物可由通式（I）表示： 1 其中 R 1 是 Me、Et 或 PhCH 2 ; R 2 是 H、PhCH 2 或 6-Me-3-Py-(CH 2 ) 2 和 R 3 带虚线的实线，即 +E,uns - - - 代表单键或双键及其与药理学上可接受的酸和季衍生物的盐。